Eveglip 50 Tablet contains Vildagliptin 50mg, an oral antidiabetic medication used to manage type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the levels of incretin hormones. These hormones help regulate blood glucose by enhancing insulin secretion from the pancreas in response to meals and by suppressing glucagon release, thereby reducing hepatic glucose production. Eveglip 50 is typically prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin or sulfonylureas. It is important to take the tablet as directed by a healthcare professional, usually once or twice daily, with or without food. Common side effects may include headache, dizziness, or mild gastrointestinal discomfort, but serious adverse effects are rare. Regular monitoring of blood glucose levels and kidney function is recommended during treatment. Eveglip 50 should be used cautiously in patients with renal impairment and is not indicated for type 1 diabetes or diabetic ketoacidosis. Always consult a healthcare provider before starting or adjusting the dosage.